New data for Abbott's Investigational High Sensitive Troponin Test shows it may help doctors predict heart attack risk.
Full press release follows.
SOURCE: Abbott
HOUSTON,
July 30, 2013 /PRNewswire/ -- Abbott (NYSE: ABT) announced today promising
results from a study evaluating its High Sensitive Troponin-I (hsTnI) assay
presented at this year's American Association for Clinical Chemistry (AACC)
annual meeting in Houston, Texas. The study, conducted by researchers at
Brigham and Women's Hospital, demonstrated that Abbott's hsTnI test (currently
for research-use only in the United States) may help doctors predict which
patients presenting with symptoms of a heart attack, such as severe chest pain,
are at a higher risk for having a heart attack 30 days later.
A
concern for patients who present with severe chest pain is that they are more
likely to experience another cardiovascular event within a few weeks or months.
Researchers at Brigham and Women's Hospital evaluated the performance of a
hsTnI assay (Abbott, ARCHITECT) with the performance of a fourth generation
troponin T assay (Roche, TnT) among 4,695 patients presenting with severe chest
pain and found that the hsTnI assay identified more patients at higher risk of
recurrent heart attack, even at very low troponin concentrations.
"The
ability to identify patients at higher risk for another heart attack or
cardiovascular death is an essential step in their prevention," said Dr.
Petr Jarolim, M.D., Ph.D., one of the key authors of the study and Medical
Director, Clinical Chemistry and Laboratory Control, Brigham and Women's
Hospital. "This study demonstrates that the new high sensitivity cardiac
troponin assays are efficient tools for classifying patients, allowing doctors
to provide more aggressive treatment of those at higher risk."
Cardiac
troponin, a protein found in the heart muscle, is considered the preferred
biomarker used to identify suspected heart attacks, because it can detect
injury to the heart.1 Abbott's ARCHITECT STAT
hsTnI assay can measure very low levels of the protein, which allows doctors to
evaluate whether or not patients are having a heart attack within two to four
hours after presentation.2 This
faster evaluation could allow doctors to reduce the time to diagnosis and
treatment by several hours when compared to standard troponin tests.
"This
study adds to the clinical evidence confirming the advantages of Abbott's high
sensitive troponin test to provide more insight to clinicians about which
patients are at greater risk for a future heart attack as compared to
contemporary tests," said John Frels, PhD, divisional vice president,
Diagnostics Research, Abbott. "This is important information for patient
care because it may help doctors focus on the patients at greater risk for appropriate
management."
The
abstract for this study was selected as the first annual recipient of the
Biomarkers of Acute Cardiac Disease Division Outstanding Abstract Award. The
committee awarded a grant for outstanding abstract to one of the key authors of
the study, Dr. Petr Jarolim (Brigham and Women's Hospital).
The
ARCHITECT STAT hsTnI assay is commercially available in Europe and runs
on Abbott's fully-automated ARCHITECT family of analyzers.
About
Abbott Diagnostics
Abbott
is a global leader in in vitro diagnostics and offers a broad range of
innovative instrument systems and tests for hospitals, reference labs,
molecular labs, blood banks, physician offices and clinics. With more than
22,000 customers in more than 100 countries, Abbott's diagnostic products offer
customers automation, convenience, bedside testing, cost effectiveness, and
flexibility. Abbott has helped transform the practice of medical diagnosis from
an art to a science through the company's commitment to improving patient care
and lowering costs.
About
Abbott
Abbott
is a global healthcare company devoted to improving life through the
development of products and technologies that span the breadth of healthcare.
With a portfolio of leading, science-based offerings in diagnostics, medical
devices, nutritionals and branded generic pharmaceuticals, Abbott serves people
in more than 150 countries and employs approximately 70,000 people.
Visit
Abbott at www.abbott.com and connect
with us on Twitter at @AbbottNews.
1 Thygesen K, Alpert JS, Jaffe AS et
al. Third universal definition of myocardial infarction. European Heart
Journal. 2012; 33:2551-2567.
2 Abbott ARCHITECT STAT High
Sensitive Troponin-I Product Insert (PI), January 2013.
SOURCE
Abbott
CONTACT:
Media, Darcy Ross, (847) 937-3655 (office), (224) 475-7673 (mobile), or Jessica
Masuga, (847) 935-0650 (office), (847) 970-1391 (mobile), or Financial, Tina
Ventura, (847) 935-9390
Web Site: http://www.abbott.com
No comments:
Post a Comment